Chronic Gastrointestinal Graft vs Host Disease
Gastroenterology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SoligenixorBec
Clinical Trials (1)
Total enrollment: 2 patients across 1 trials
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Start: Dec 2013Est. completion: May 20152 patients
Phase 2Terminated
Related Jobs in Gastroenterology
Specialty Representative, Gastroenterology – Minneapolis, Minnesota
AbbVie
Remote
11h ago
Head of Drug Product Development
Ironwood Pharmaceuticals
Boston, Massachusetts, United States
12h ago
$246K - $287K/yr
Regulatory Affairs Associate
Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday
Key Account Director, Diagnostics and Research
Tempus
Remote
Yesterday
$150K - $200K/yr
QA Operation Platform Lead
Johnson & Johnson
Yokneam, Haifa District, Israel
Yesterday
Value Architecture & Engineering Lead
Johnson & Johnson
Titusville, New Jersey, United States of America
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space